These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30775940)

  • 1. Why have transgenic rodent models failed to successfully mimic Alzheimer's disease. How can we develop effective drugs without them?
    Franco R; Martínez-Pinilla E; Navarro G
    Expert Opin Drug Discov; 2019 Apr; 14(4):327-330. PubMed ID: 30775940
    [No Abstract]   [Full Text] [Related]  

  • 2. Rodent models for Alzheimer's disease drug discovery.
    Puzzo D; Gulisano W; Palmeri A; Arancio O
    Expert Opin Drug Discov; 2015 Jul; 10(7):703-11. PubMed ID: 25927677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How efficient are rodent models for Alzheimer's disease drug discovery?
    Guo B; Zhou Q
    Expert Opin Drug Discov; 2018 Feb; 13(2):113-115. PubMed ID: 29082769
    [No Abstract]   [Full Text] [Related]  

  • 4. How does a researcher choose the best rodent model for their Alzheimer's disease drug discovery study?
    Van Dam D; De Deyn PP
    Expert Opin Drug Discov; 2020 Mar; 15(3):269-271. PubMed ID: 31592694
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of tau-directed small molecule modulators for Alzheimer's disease: a recent patent review (2014-2018).
    Lee HE; Lim D; Lee JY; Lim SM; Pae AN
    Pharm Pat Anal; 2019 Jan; 8(1):15-39. PubMed ID: 30870110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic aspects in selecting a suitable transgenic rodent model for Alzheimer's disease.
    Balmus IM; Ciobica A; Negura A; Negura L; Anton E
    Psychiatr Danub; 2015 Dec; 27(4):338-45. PubMed ID: 26609645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease.
    Camins A; Ettcheto M; Busquets O; Manzine PR; Castro-Torres RD; Beas-Zarate C; Verdaguer E; Sureda FX; Bulló M; Olloquequi J; Auladell C; Folch J
    Expert Opin Investig Drugs; 2019 Jan; 28(1):93-97. PubMed ID: 30480461
    [No Abstract]   [Full Text] [Related]  

  • 8. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs.
    Yamada K; Nabeshima T
    Pharmacol Ther; 2000 Nov; 88(2):93-113. PubMed ID: 11150591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease in the zebrafish: where can we take it?
    Caramillo EM; Echevarria DJ
    Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):179-186. PubMed ID: 28177980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of transgenic and nontransgenic animal models in Alzheimer's disease drug research and development.
    Mhillaj E; Cuomo V; Mancuso C
    Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):95-111. PubMed ID: 28177983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging preclinical models for the development of Alzheimer disease therapeutics.
    Scearce-Levie K; Sanchez PE; Lewcock JW
    Nat Rev Drug Discov; 2020 Jul; 19(7):447-462. PubMed ID: 32612262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer's Disease.
    Dubey SK; Ram MS; Krishna KV; Saha RN; Singhvi G; Agrawal M; Ajazuddin ; Saraf S; Saraf S; Alexander A
    Cell Mol Neurobiol; 2019 Mar; 39(2):181-209. PubMed ID: 30671696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models in the development of symptomatic and preventive drug therapies for Alzheimer's disease.
    Riekkinen P; Schmidt BH; van der Staay FJ
    Ann Med; 1998 Dec; 30(6):566-76. PubMed ID: 9920360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?
    Cacabelos R
    Expert Opin Drug Discov; 2018 Jun; 13(6):523-538. PubMed ID: 29607687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease: future drug development and the blood-brain barrier.
    Pardridge WM
    Expert Opin Investig Drugs; 2019 Jul; 28(7):569-572. PubMed ID: 31155971
    [No Abstract]   [Full Text] [Related]  

  • 16. New Approaches to Develop Drug Treatment for Alzheimer's Disease: Targeting Calcium Dysregulation.
    Wei H
    Curr Alzheimer Res; 2020; 17(4):311-312. PubMed ID: 32623998
    [No Abstract]   [Full Text] [Related]  

  • 17. Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
    Conrado DJ; Duvvuri S; Geerts H; Burton J; Biesdorf C; Ahamadi M; Macha S; Hather G; Francisco Morales J; Podichetty J; Nicholas T; Stephenson D; Trame M; Romero K; Corrigan B;
    Clin Pharmacol Ther; 2020 Apr; 107(4):796-805. PubMed ID: 31955409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer's disease.
    Silva CFM; Pinto DCGA; Silva AMS
    Expert Opin Drug Discov; 2018 Dec; 13(12):1141-1151. PubMed ID: 30430870
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
    Imbimbo BP; Watling M
    Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
    [No Abstract]   [Full Text] [Related]  

  • 20. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes.
    Cummings J
    Clin Transl Sci; 2018 Mar; 11(2):147-152. PubMed ID: 28767185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.